David Craig

David Craig is CEO of Sarcomatrix Therapeutics, a biotechnology company developing small molecule therapies for muscle diseases. He previously held executive roles at Amgen, Gilead and Alexion, and advocates for pragmatic, multi-modal innovation in rare disease drug development.